Alefacept

N/A

Report date: 2024/07/25 20:00:05
First In Class

Base Information

Drug NameAlefacept
Drug Alias Name阿来法塞alefacept阿法赛特LFA3-Fc阿来西普 +[16] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionT-cell surface antigen CD2 inhibitors
TargetsT-cell surface antigen CD2
Therapy Area/IndicationsPlaque psoriasisGraft vs Host DiseaseDiabetes Mellitus, Type 1 +[6] 
Global Approved IndicationsPsoriasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2003/01/30
Country/TerritoryBelgiumBulgariaCanada +[13] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteUniversity Of Medicine And Dentistry Of New JerseyAstellas Pharma Us Inc +[7] 
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisGraft vs Host DiseaseDiabetes Mellitus, Type 1 +[6] 

Other Information

ATC CodeL04AA15
Related LinksWikipediaDrugBankKEGG